Clinical Trials
Since its inception, the MMRC has facilitated 19 Phase I and Phase II clinical trials. These trials include several combination approaches and novel compounds that are thought to be active against high-priority targets.
2011
- Phase II Carfilzomib + Revlimid + Dex
- Phase II Treanda + Revlimid + Dex
- Phase I AT7519 + Velcade
- Phase I Panobinostat + Carfilzomib
- Phase I Ganetespib
- Phase I MLN9708 + Rev-Dex
- Phase I GSK2110183 + Vel + Dex
- Phase I Pomalidomide + Vel-Dex
2010
- Phase I INK 128
- Phase I Siltuximab in Smoldering MM
- Phase II Carfilzomib/Rev/Dex Front Line
- Phase I Array 520/Velcade
- Phase I AT7519 + Velcade
- Phase I Treanda/Rev-Dex
2009
- Phase Ib Elotuzumab w/ Rev-Dex
- Phase II Pomalidomide +/- Dex
- Phase I Carfilzomib/Rev/Dex Front Line
- Phase I MLNM8237/Velcade
- Phase II Rev/Velcade/Doxil/Dex Front Line
- Phase I PD0332991/Velcade
2008
- Phase II Merck Zolinza-Velcade
- PRESS RELEASE
- Multiple Myeloma Research Consortium (MMRC) and Merck initiate Phase II Trial of Zolinza with Velcade in Relapsed and Refractory Multiple Myeloma Patients
- Phase II Wyeth Torisel-Velcade
- Phase I Elotuzumab-Revlimid-Dex
- Phase I Celgene Pomalidomide (CC-4047)
- PRESS RELEASE
- The Multiple Myeloma Research Consortium (MMRC) Partners with Celgene Corporation on Phase I/II Trial of Pomalidomide (CC-4047) in Relapsed and Refractory Multiple Myeloma Patients
- Phase I PDL Elotuzumab-Velcade-Dex
- PRESS RELEASE
- The Multiple Myeloma Research Consortium (MMRC) Announces the Initiation of Phase I/II Study of Elotuzumab (Huluc63) Monoclonal Antibody in Combination with Velcade
- Phase I RVDD (upfront)
- PRESS RELEASE
- The Multiple Myeloma Research Consortium (MMRC) Announces Initiation of First Four-Drug Combination Study to Treat Newly Diagnosed Multiple Myeloma Patients
- Phase Ib LBH859-Revlimid-Dex
- PRESS RELEASE
- Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2007
- Phase Ib Novartis LBH589-Velcade
- ABSTRACT (ASH 2781)
- A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
- Phase I Semafore SF1126
- Phase II Proteolix Carfilzomib (relapsed)
- ABSTRACT (ASH 865)
- Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)
- Phase II Proteolix Carfilzomib (relapsed/refractory)
- PRESS RELEASE
- The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
- ABSTRACT (ASH 864)
- Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)
- Phase I Wyeth Torisel-Velcade
- PRESS RELEASE
- The Multiple Myeloma Research Consortium Commences Phase I/II Combination Study for the Treatment of Multiple Myeloma
- ABSTRACT (ASH 3696)
- Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma
- Phase I Ortho Tipifarnib-Velcade
- PRESS RELEASE
- Multiple Myeloma Research Consortium (MMRC), Emory University Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
- ABSTRACT (ASH 3706)
- A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
- Phase II Novartis LBH589
- PRESS RELEASE
- Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
- ABSTRACT (ASH 2774)
- A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma
2005 – 2006
- Phase I Trial of NPI-0052
- PRESS RELEASE
- The Multiple Myeloma Research Consortium and Nereus Pharmaceuticals Initiate Clinical Trial Investigating NPI-0052 to Treat Multiple Myeloma
- ABSTRACT (ASH 2270)
- Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma
- Phase I Keryx Perifosine-Revlimid-Dex
- PRESS RELEASE
- The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
- ABSTRACT (ASH 3691)
- Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)
- Phase I Novartis TKI258 (CHIR-258)
- PRESS RELEASE
- Chiron and the Multiple Myeloma Research Consortium Announce Initiation of Phase I Clinical Trial for CHIR-258
- ABSTRACT (MMRC Publications)
- Phase I trial of chir-258 in multiple myeloma
